Showing results (141-150 of 264) with videos related to

Sort By:
Pageof 27
European Urology|January 16, 2009
Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patientsHarriet C Thoeny, Maria Triantafyllou, Frederic D Birkhaeuser, et al.
European Urology|August 7, 2013
Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancerFrédéric D Birkhäuser, Urs E Studer, Johannes M Froehlich, et al.
Biometrical Journal. Biometrische Zeitschrift|September 17, 2020
A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisonsEva Cantagallo, Mickaël De Backer, Michal Kicinski, et al.
Biometrical Journal. Biometrische Zeitschrift|February 22, 2021
Correcting the bias of the net benefit estimator due to right-censored observationsJulien Péron, Maryam Idlhaj, Delphine Maucort-Boulch, et al.
European Urology|May 4, 2012
Occlusion of seminal vesicles increases sexual activity in a mouse modelFrédéric D Birkhäuser, Celine Schumacher, Roland Seiler, et al.
Acta Oncologica (Stockholm, Sweden)|June 24, 2008
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladderPhilip M Poortmans, Pierre Richaud, Laurence Collette, et al.
Japanese Journal of Clinical Oncology|February 8, 2017
Collaboration between EORTC and JCOG-how to accelerate global clinical research partnershipKozo Kataoka, Kenichi Nakamura, Carmela Caballero, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 6, 2008
EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost armBrigitta G Baumert, Michael Brada, Jacques Bernier, et al.
The Journal of Urology|November 22, 2017
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer StudiesMarco Moschini, Shahrokh F Shariat, Morgan Rouprêt, et al.
European Urology|October 1, 2008
Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial)Fritz H Schröder, Karl-Heinz Kurth, Sophie D Fossa, et al.
Pageof 27